Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation

Mayako Uchida, Koji Kato, Hiroaki Ikesue, Kimiko Ichinose, Hiromi Hiraiwa, Asako Sakurai, Tsuyoshi Muta, Katsuto Takenaka, Hiromi Iwasaki, Toshihiro Miyamoto, Takanori Teshima, Motoaki Shiratsuchi, Kimitaka Suetsugu, Kenichiro Nagata, Nobuaki Egashira, Koichi Akashi, Ryozo Oishi

研究成果: ジャーナルへの寄稿記事

6 引用 (Scopus)

抄録

STUDY OBJECTIVE To evaluate the efficacy and safety of aprepitant added to standard antiemetic regimens used in high-dose chemotherapy for allogeneic hematopoietic stem cell transplantation (allo- HSCT). DESIGN Retrospective medical record review. SETTING Hematology ward of a university hospital in Japan. PATIENTS Of 88 patients treated with high-dose chemotherapy followed by allo-HSCT, 46 received aprepitant and granisetron as antiemetic therapy (between April 1, 2010, and December 31, 2011), and 42 received granisetron alone (between April 1, 2008, and March 31, 2010). INTERVENTIONS Patients in both groups received 3 mg of granisetron intravenously 30 minutes before the administration of anticancer drugs. In the aprepitant group, 125 mg of aprepitant was administered orally 60-90 minutes before the administration of the first moderately to highly emetogenic anticancer drug. On the following days, 80 mg of aprepitant was administered orally every morning. The mean administration duration of aprepitant was 3.3 days (range 3-6 days). MEASUREMENTS AND MAIN RESULTS The primary objective was to evaluate the percentage of patients who achieved complete response (CR; no vomiting and none to mild nausea). The CR rate in the aprepitant group was significantly higher than that in the control group (48% vs 24%, p=0.02). Multivariate analysis showed that nonprophylactic use of aprepitant was associated with failure to achieve CR (odds ratio [OR] 2.92; 95% confidence interval [CI] 1.13-7.99, p=0.03). The frequency of abdominal pain was lower in the aprepitant group (9% vs 25%, p=0.03). Rates of other frequently observed adverse drug events were similar between groups. There was no significant difference in neutrophil engraftment (median 18 vs 17 days), platelet engraftment (median 32 vs 32 days), the incidence of acute graft-versus-host-disease (63% vs 55%, p=0.52), viral infection (74% vs 67%, p=0.49), or 1-year overall survival (63% vs 62%, p=0.90) between the two groups. CONCLUSIONS The addition of aprepitant to granisetron increases the antiemetic effect without influencing transplantation-related toxicities in allo-HSCT.

元の言語英語
ページ(範囲)893-901
ページ数9
ジャーナルPharmacotherapy
33
発行部数9
DOI
出版物ステータス出版済み - 9 1 2013

Fingerprint

aprepitant
Hematopoietic Stem Cell Transplantation
Safety
Granisetron
Antiemetics
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

これを引用

Uchida, M., Kato, K., Ikesue, H., Ichinose, K., Hiraiwa, H., Sakurai, A., ... Oishi, R. (2013). Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation. Pharmacotherapy, 33(9), 893-901. https://doi.org/10.1002/phar.1294

Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation. / Uchida, Mayako; Kato, Koji; Ikesue, Hiroaki; Ichinose, Kimiko; Hiraiwa, Hiromi; Sakurai, Asako; Muta, Tsuyoshi; Takenaka, Katsuto; Iwasaki, Hiromi; Miyamoto, Toshihiro; Teshima, Takanori; Shiratsuchi, Motoaki; Suetsugu, Kimitaka; Nagata, Kenichiro; Egashira, Nobuaki; Akashi, Koichi; Oishi, Ryozo.

:: Pharmacotherapy, 巻 33, 番号 9, 01.09.2013, p. 893-901.

研究成果: ジャーナルへの寄稿記事

Uchida, M, Kato, K, Ikesue, H, Ichinose, K, Hiraiwa, H, Sakurai, A, Muta, T, Takenaka, K, Iwasaki, H, Miyamoto, T, Teshima, T, Shiratsuchi, M, Suetsugu, K, Nagata, K, Egashira, N, Akashi, K & Oishi, R 2013, 'Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation', Pharmacotherapy, 巻. 33, 番号 9, pp. 893-901. https://doi.org/10.1002/phar.1294
Uchida, Mayako ; Kato, Koji ; Ikesue, Hiroaki ; Ichinose, Kimiko ; Hiraiwa, Hiromi ; Sakurai, Asako ; Muta, Tsuyoshi ; Takenaka, Katsuto ; Iwasaki, Hiromi ; Miyamoto, Toshihiro ; Teshima, Takanori ; Shiratsuchi, Motoaki ; Suetsugu, Kimitaka ; Nagata, Kenichiro ; Egashira, Nobuaki ; Akashi, Koichi ; Oishi, Ryozo. / Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation. :: Pharmacotherapy. 2013 ; 巻 33, 番号 9. pp. 893-901.
@article{e3935a3fd14942bc8b17c5ed56135e7a,
title = "Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation",
abstract = "STUDY OBJECTIVE To evaluate the efficacy and safety of aprepitant added to standard antiemetic regimens used in high-dose chemotherapy for allogeneic hematopoietic stem cell transplantation (allo- HSCT). DESIGN Retrospective medical record review. SETTING Hematology ward of a university hospital in Japan. PATIENTS Of 88 patients treated with high-dose chemotherapy followed by allo-HSCT, 46 received aprepitant and granisetron as antiemetic therapy (between April 1, 2010, and December 31, 2011), and 42 received granisetron alone (between April 1, 2008, and March 31, 2010). INTERVENTIONS Patients in both groups received 3 mg of granisetron intravenously 30 minutes before the administration of anticancer drugs. In the aprepitant group, 125 mg of aprepitant was administered orally 60-90 minutes before the administration of the first moderately to highly emetogenic anticancer drug. On the following days, 80 mg of aprepitant was administered orally every morning. The mean administration duration of aprepitant was 3.3 days (range 3-6 days). MEASUREMENTS AND MAIN RESULTS The primary objective was to evaluate the percentage of patients who achieved complete response (CR; no vomiting and none to mild nausea). The CR rate in the aprepitant group was significantly higher than that in the control group (48{\%} vs 24{\%}, p=0.02). Multivariate analysis showed that nonprophylactic use of aprepitant was associated with failure to achieve CR (odds ratio [OR] 2.92; 95{\%} confidence interval [CI] 1.13-7.99, p=0.03). The frequency of abdominal pain was lower in the aprepitant group (9{\%} vs 25{\%}, p=0.03). Rates of other frequently observed adverse drug events were similar between groups. There was no significant difference in neutrophil engraftment (median 18 vs 17 days), platelet engraftment (median 32 vs 32 days), the incidence of acute graft-versus-host-disease (63{\%} vs 55{\%}, p=0.52), viral infection (74{\%} vs 67{\%}, p=0.49), or 1-year overall survival (63{\%} vs 62{\%}, p=0.90) between the two groups. CONCLUSIONS The addition of aprepitant to granisetron increases the antiemetic effect without influencing transplantation-related toxicities in allo-HSCT.",
author = "Mayako Uchida and Koji Kato and Hiroaki Ikesue and Kimiko Ichinose and Hiromi Hiraiwa and Asako Sakurai and Tsuyoshi Muta and Katsuto Takenaka and Hiromi Iwasaki and Toshihiro Miyamoto and Takanori Teshima and Motoaki Shiratsuchi and Kimitaka Suetsugu and Kenichiro Nagata and Nobuaki Egashira and Koichi Akashi and Ryozo Oishi",
year = "2013",
month = "9",
day = "1",
doi = "10.1002/phar.1294",
language = "English",
volume = "33",
pages = "893--901",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "9",

}

TY - JOUR

T1 - Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation

AU - Uchida, Mayako

AU - Kato, Koji

AU - Ikesue, Hiroaki

AU - Ichinose, Kimiko

AU - Hiraiwa, Hiromi

AU - Sakurai, Asako

AU - Muta, Tsuyoshi

AU - Takenaka, Katsuto

AU - Iwasaki, Hiromi

AU - Miyamoto, Toshihiro

AU - Teshima, Takanori

AU - Shiratsuchi, Motoaki

AU - Suetsugu, Kimitaka

AU - Nagata, Kenichiro

AU - Egashira, Nobuaki

AU - Akashi, Koichi

AU - Oishi, Ryozo

PY - 2013/9/1

Y1 - 2013/9/1

N2 - STUDY OBJECTIVE To evaluate the efficacy and safety of aprepitant added to standard antiemetic regimens used in high-dose chemotherapy for allogeneic hematopoietic stem cell transplantation (allo- HSCT). DESIGN Retrospective medical record review. SETTING Hematology ward of a university hospital in Japan. PATIENTS Of 88 patients treated with high-dose chemotherapy followed by allo-HSCT, 46 received aprepitant and granisetron as antiemetic therapy (between April 1, 2010, and December 31, 2011), and 42 received granisetron alone (between April 1, 2008, and March 31, 2010). INTERVENTIONS Patients in both groups received 3 mg of granisetron intravenously 30 minutes before the administration of anticancer drugs. In the aprepitant group, 125 mg of aprepitant was administered orally 60-90 minutes before the administration of the first moderately to highly emetogenic anticancer drug. On the following days, 80 mg of aprepitant was administered orally every morning. The mean administration duration of aprepitant was 3.3 days (range 3-6 days). MEASUREMENTS AND MAIN RESULTS The primary objective was to evaluate the percentage of patients who achieved complete response (CR; no vomiting and none to mild nausea). The CR rate in the aprepitant group was significantly higher than that in the control group (48% vs 24%, p=0.02). Multivariate analysis showed that nonprophylactic use of aprepitant was associated with failure to achieve CR (odds ratio [OR] 2.92; 95% confidence interval [CI] 1.13-7.99, p=0.03). The frequency of abdominal pain was lower in the aprepitant group (9% vs 25%, p=0.03). Rates of other frequently observed adverse drug events were similar between groups. There was no significant difference in neutrophil engraftment (median 18 vs 17 days), platelet engraftment (median 32 vs 32 days), the incidence of acute graft-versus-host-disease (63% vs 55%, p=0.52), viral infection (74% vs 67%, p=0.49), or 1-year overall survival (63% vs 62%, p=0.90) between the two groups. CONCLUSIONS The addition of aprepitant to granisetron increases the antiemetic effect without influencing transplantation-related toxicities in allo-HSCT.

AB - STUDY OBJECTIVE To evaluate the efficacy and safety of aprepitant added to standard antiemetic regimens used in high-dose chemotherapy for allogeneic hematopoietic stem cell transplantation (allo- HSCT). DESIGN Retrospective medical record review. SETTING Hematology ward of a university hospital in Japan. PATIENTS Of 88 patients treated with high-dose chemotherapy followed by allo-HSCT, 46 received aprepitant and granisetron as antiemetic therapy (between April 1, 2010, and December 31, 2011), and 42 received granisetron alone (between April 1, 2008, and March 31, 2010). INTERVENTIONS Patients in both groups received 3 mg of granisetron intravenously 30 minutes before the administration of anticancer drugs. In the aprepitant group, 125 mg of aprepitant was administered orally 60-90 minutes before the administration of the first moderately to highly emetogenic anticancer drug. On the following days, 80 mg of aprepitant was administered orally every morning. The mean administration duration of aprepitant was 3.3 days (range 3-6 days). MEASUREMENTS AND MAIN RESULTS The primary objective was to evaluate the percentage of patients who achieved complete response (CR; no vomiting and none to mild nausea). The CR rate in the aprepitant group was significantly higher than that in the control group (48% vs 24%, p=0.02). Multivariate analysis showed that nonprophylactic use of aprepitant was associated with failure to achieve CR (odds ratio [OR] 2.92; 95% confidence interval [CI] 1.13-7.99, p=0.03). The frequency of abdominal pain was lower in the aprepitant group (9% vs 25%, p=0.03). Rates of other frequently observed adverse drug events were similar between groups. There was no significant difference in neutrophil engraftment (median 18 vs 17 days), platelet engraftment (median 32 vs 32 days), the incidence of acute graft-versus-host-disease (63% vs 55%, p=0.52), viral infection (74% vs 67%, p=0.49), or 1-year overall survival (63% vs 62%, p=0.90) between the two groups. CONCLUSIONS The addition of aprepitant to granisetron increases the antiemetic effect without influencing transplantation-related toxicities in allo-HSCT.

UR - http://www.scopus.com/inward/record.url?scp=84885336717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885336717&partnerID=8YFLogxK

U2 - 10.1002/phar.1294

DO - 10.1002/phar.1294

M3 - Article

C2 - 23712662

AN - SCOPUS:84885336717

VL - 33

SP - 893

EP - 901

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 9

ER -